Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1669-1677

  Wiesner, James B ^a   Ugarkar, Bheemarao G ^a   Castellino, Angelo J ^a,b   Barankiewicz, Jerzy ^a,c   Dumas, David P ^a,d   Gruber, Harry E ^a,e   Foster, Alan C ^a,f   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

^b Formerly CombiChem Inc   (United States)

^c Cypros Pharmaceutical Corporation   (United States)

^d LG Biomedical Institute   (United States)

^e Intervu Inc   (United States)

^f NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ANILINO 5 PHENYLPYRROLO[2,3 D]PYRIMIDINE 7 (5 DEOXYRIBOSIDE); 5 IODOTUBERCIDIN; 5' AMINO 5' DEOXYADENOSINE; 5' DEOXY 5 IODOTUBERCIDIN; 8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE KINASE INHIBITOR; DEOXYADENOSINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THEOPHYLLINE; TUBERCIDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTICONVULSANT THERAPY; ARTICLE; BRADYCARDIA; DRUG EFFICACY; ELECTRIC SHOCK; ENZYME INHIBITION; EPILEPTIC DISCHARGE; HYPOTENSION; HYPOTHERMIA; NEGATIVE FEEDBACK; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY;

ADENOSINE; ADENOSINE KINASE; ANIMALS; ANTICONVULSANTS; CATTLE; CELLS, CULTURED; DEOXYADENOSINES; ELECTROSHOCK; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; MALE; MICROCIRCULATION; MOTOR ACTIVITY; NEOCORTEX; PYRIMIDINES; RADIOLIGAND ASSAY; RATS; RATS, INBRED STRAINS; RECOMBINANT PROTEINS; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCIDIN;

EID: 0033060914     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aram JA and Lodge D (1988) Validation of a neocortical slice preparation for the study of epileptiform activity. J Neurosci Methods 23:211-224.
2. Ashton D, De Prins E, Willems R, Van Belle H and Wauquier A (1988) Anticonvulsant action of the nucleoside transport inhibitor, soluflazine, on synaptic and non-synaptic epileptogenesis in the guinea-pig hippocampus. Epilepsy Res 2:65-71.
3. Ault B and Wang CM (1986) Adenosine inhibits epileptiform activity arising in hippocampal area CA3. Br J Pharmacol 87:695-703.
4. Barankiewicz J, Jimenez R, Ronlov G, Magill M and Gruber HE (1990) Alteration of purine metabolism by AICA-riboside in human B lymphoblasts. Arch Biochem Biophys 282:377-385.
5. Brownhill, VR, Hourani, SM and Kitchen, I (1996) Differential ontogeny of adenosine receptors in the longitudinal muscle and muscularis mucosae of the rat isolated duodenum. Eur J Pharmacol 317:321-328.
6. 3H] phenylxanthine. Proc Natl Acad Sci USA 77:5547-5551.
7. 3H]NECA in rat striatal membranes. Mol Pharmacol 29:331-346.
8. Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Di Pasquale G and Carson DA (1993) New adenosine kinase inhibitors with oral antiinflanunatory activity: Synthesis and biological evaluation. J Med Chem 36:3424-3430.
9. 2 receptors in vivo. Biochem Pharmacol 35:3021-3029.
10. Dragunow M (1986) Adenosine: The brain's natural anticonvulsant? Trends Pharmacol Sci 7:128-130.
11. Dunwiddie TV and Worth T (1982) Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther 220:70-76.
12. During MJ and Spencer DD (1992) Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 32:618-624.
13. Erion MD, Bookser BC and Rao KS (1998) Novel inhibitors of adenosine monophosphate deaminase. U.S. Patent no. 5,731,432.
14. Erion MD, Ugarkar BG, DaRe J, Castellino AJ, Fujitake JM, Dixon R, Appleman JR and Wiesner JB (1997) Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleosides Nucleotides 16:1013-1021.
15. 2B receptors. Pharmacol Rev 49:381-402.
16. Foster AC, Miller LP and Wiesner JB (1995) Regulation of endogenous adenosine levels in the CNS: Potential for therapy in stroke, epilepsy and pain, in Purine and Pyrimidine Metabolism in Man, VII (Sahota A and Taylor M eds) pp 427-430, Plenum Press, New York.
17. Geiger JD, Lewis JL, Maclntyre CJ and Nagy JI (1987) Pharmacokinetics of 2′-deoxycoformycin, and inhibitor of adenosine deaminase, in the rat. Neuropharmacology 26:1383-1387.
18. Greene RW and Haas HL (1991) The electrophysiology of adenosine in the mammalian central nervous system. Prog Neurobiol 36:329-341.
19. 2 receptors in rat brain. J Pharmacol Exp Ther 261:888-893.
20. Knutsen LJS and Murray TF (1997) Adenosine and ATP in epilepsy, in Purinergic Approaches in Experimental Therapeutics (Jacobson KA and Jarvis MF eds) pp 423-447, Wiley-Liss, New York.
21. Kostopoulos G, Drapeau C, Avoli M, Olivier A and Villemeure JG (1989) Endogenous adenosine can reduce epileptiform activity in the human epileptogenic cortex maintained in vitro. Neurosci Lett 106:119-124.
22. Lloyd HG and Fredholm BB (1995) Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int 26:387-395.
23. Malhotra J and Gupta YK (1997) Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rate. Br J Pharmacol 120:282-288.
24. 3H]nitrobenzyl-thioinosine binding as a probe for the study of adenosine uptake sites in brain. J Neurochem 39:184-191.
25. Muller CE and Stein B (1996) Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr Pharm Design 2:501-530.
26. 1 adenosine receptor mediated modulation of seizure susceptibility, in Neurotransmitters, Seizures and Epilepsy III (Nistico G ed) pp 341-353, Raven Press, New York.
27. 1 adenosine receptor-mediated block of epileptiform activity induced in zero magnesium in rat neocortex in vitro. Epilepsy Res 2:294-301.
28. Phillis JW and Wu PH (1983) Roles of adenosine and adenine nucleotides in the central nervous system, in Physiology and Pharmacology of Adenosine Derivatives (Daly JW, Phillis JW, Kuroda Y, Shimizu H and Ui M eds) pp 219-236, Raven Press, New York.
29. Schaeffer HJ and Schwender CF (1974) Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J Med Chem 17:6-8.
30. Schultz V and Lowenstein JM (1978) The purine nucleotide cycle. Studies of ammonia production and interconversions of adenine and hypoxanthine nucleotides and nucleosides by rat brain in situ. J Biol Chem 253:1938-1943.
31. Spychala J, Datta NS, Takabayashi K, Datta M, Fox IH, Gribbin T and Mitchell BS (1996) Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci USA 93:1232-1237.
32. Swinyard EA, Woodhead JH, White HS and Franklin MR (1989) Experimental selection, quantification, and evaluation of anticonvulsants, in Antiepileptic Drugs, 3rd ed. (Levy R, Mattson R, Meldrum B, Penry JK and Dreifuss FE eds) pp 85-102, Raven Press, New York.
33. Tallarida RJ and Murray RB (1987) Manual of Pharmacologie Calculations with Computer Programs, 2nd ed., Springer-Verlag, New York.
34. Thompson SM, Haas HL and Gahwiler BH (1992) Comparison of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus in vitro. J Physiol (Lond) 451:347-363.
35. Upton N (1994) Mechanisms of action of new antiepileptic drugs: Rational design and serendipitous findings. Trends Pharmacol Sci 15:456-463.
36. White HS (1997) Mechanisms of action of established and newer anti-epileptic drugs, in The Epilepsies II (Porter RJ and Chadwick DC eds) pp 1-30, Butterworth-Heinemann, London.
37. Winn HR, Welsh JE, Rubio R and Berne RM (1980) Changes in brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ Res 47:568-577.
38. Wu LG and Saggau P (1994) Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus. Neuron 12:1139-1148.
39. Yamada Y, Goto H and Ogasawara N (1981) Adenosine kinase from human liver. Biochim Biophys Acta 660:36-43.
40. Zhang G, Franklin PH and Murray TF (1993) Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther 264:1415-1424.